AEON Biopharma (AEON) Non-Current Assets (2021 - 2026)
AEON Biopharma (AEON) posted Non-Current Assets of $2.2 million for Q4 2025, up 63.54% sequentially from $1.3 million in Q3 2025, and up 39.3% YoY from $1.6 million in Q4 2024.
AEON Biopharma (AEON) Non-Current Assets (2021 - 2026) Analysis & Trends
AEON Biopharma has reported Non-Current Assets for 5 years, with the latest figure at $2.2 million in Q4 2025.
- Quarterly Non-Current Assets rose 39.3% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.4 million (up 17.08% YoY) and the FY2025 annual result came in at $2.2 million, up 39.3% from the prior year.
- Non-Current Assets advanced to $2.2 million in Q4 2025 per AEON's latest filing, from $1.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $277.2 million in Q3 2022 and troughed at $534000.0 in Q1 2024.
- A 5-year average of $99.5 million and a median of $1.9 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets plunged 99.74% in 2023, then soared 176.78% in 2025.
- Over 5 years, Non-Current Assets stood at $276.1 million in 2021, then slumped by 99.66% to $940000.0 in 2022, then plunged by 33.72% to $623000.0 in 2023, then soared by 149.12% to $1.6 million in 2024, then jumped by 39.3% to $2.2 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $2.2 million, $1.3 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | AEON Biopharma | 9.71 Mn | 6.28 Mn | - | 1.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.92 Mn |
| Dec 31, 2025 | 2.16 Mn |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.48 Mn |
| Dec 31, 2024 | 1.55 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Jun 30, 2024 | 1.72 Mn |
| Mar 31, 2024 | 534,000.00 |
| Dec 31, 2023 | 623,000.00 |
| Sep 30, 2023 | 708,000.00 |
| Jun 30, 2023 | 21.19 Mn |
| Mar 31, 2023 | 21.07 Mn |
| Dec 31, 2022 | 940,000.00 |
| Sep 30, 2022 | 277.16 Mn |
| Jun 30, 2022 | 276.27 Mn |
| Mar 31, 2022 | 276.13 Mn |
| Dec 31, 2021 | 276.11 Mn |
| Sep 30, 2021 | 276.17 Mn |
| Jun 30, 2021 | 276.23 Mn |